<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460357</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Pertussis Outbreak During 2023 in Gipuzkoa, North Spain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1192</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101192</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pertussis has re-emerged in many countries despite the wide use of vaccines for over 60 years. During 2023, we observed an increase in the incidence of pertussis in Gipuzkoa, north of Spain (with a population of 657,140 inhabitants), mainly affecting children between 11 and 15 years of age.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included all confirmed cases diagnosed by PCR in nasopharyngeal swab samples. The genome of seven isolates collected in 2023 was sequenced.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2018 and 2023, 884 cases of whooping cough were diagnosed. Pertussis incidence (in cases per 100,000 inhabitants) decreased from 36.7 in 2018 to no cases in 2021, increasing again to 56.8 in 2023. In 2023, the age group of 11-15 years old had the highest incidence rate of 409.3. Only 2 of the 56 children &lt; 6 years old required hospitalization, and there were no deaths. The seven isolates collected in 2023 showed the same BPagST-4 (<i>ptxA1/ptxP3/prn2/fim2-1/fim3</i>-1 allelic combination), with all of them expressing the pertactin antigen.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunity waning after the last dose of vaccination at 6 years old, together with the lack of circulation of <i>Bordetella pertussis</i> during the COVID-19 pandemic, were probably the main reasons for the high increase in the incidence of pertussis in Gipuzkoa in 2023.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marimón</LastName><ForeName>José María</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2787-7094</Identifier><AffiliationInfo><Affiliation>Biogipuzkoa Health Research Institute, Infectious Diseases Area, Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, Donostia University Hospital, 20014 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montes</LastName><ForeName>Milagrosa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6554-4912</Identifier><AffiliationInfo><Affiliation>Biogipuzkoa Health Research Institute, Infectious Diseases Area, Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, Donostia University Hospital, 20014 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizuete</LastName><ForeName>Nahikari</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0000-3621-4236</Identifier><AffiliationInfo><Affiliation>Sub-Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 20013 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez Guerrico</LastName><ForeName>Lorea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sub-Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 20013 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aginagalde</LastName><ForeName>Adrian Hugo</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0002-5879-2894</Identifier><AffiliationInfo><Affiliation>Sub-Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 20013 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology of Chronic and Communicable Diseases Group, Biogipuzkoa Health Research Institute, 20014 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mir-Cros</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-López</LastName><ForeName>Juan José</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-2419-5909</Identifier><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicente</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3553-4312</Identifier><AffiliationInfo><Affiliation>Biogipuzkoa Health Research Institute, Infectious Diseases Area, Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, Donostia University Hospital, 20014 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of the Basque Country, UPV/EHU, 20014 Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bordetella pertussis</Keyword><Keyword MajorTopicYN="N">outbreak</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460357</ArticleId><ArticleId IdType="pmc">PMC11511359</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101192</ArticleId><ArticleId IdType="pii">vaccines12101192</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mir-Cros A., Codina G., Martín-Gómez M.T., Fàbrega A., Martínez X., Jané M., Van Esso D., Cornejo T., Rodrigo C., Campins M., et al. Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain. Emerg. Infect. Dis. 2017;23:1856–1859. doi: 10.3201/eid2311.170960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2311.170960</ArticleId><ArticleId IdType="pmc">PMC5652430</ArticleId><ArticleId IdType="pubmed">29052540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchez V., Toubiana J., Guillot S., Parapertussis Study Group. El Belghiti F.A., Landier A., Armatys N., Trombert-Paolantoni S., Soares A., Rodrigues C., et al. Transient reemergence of Bordetella parapertussis in France in 2022. J. Med. Microbiol. 2024;73:001843. doi: 10.1099/jmm.0.001843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001843</ArticleId><ArticleId IdType="pubmed">38995835</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark T.A. Changing pertussis epidemiology: Everything old is new again. J. Infect. Dis. 2014;209:978–981. doi: 10.1093/infdis/jiu001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu001</ArticleId><ArticleId IdType="pubmed">24626532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauria A.M., Zabbo C.P.  StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023.  [(accessed on 22 September 2024)]. Pertussis. Available online:  http://www.ncbi.nlm.nih.gov/books/NBK519008/</Citation></Reference><Reference><Citation>Havers F.P., Moro P.L., Hariri S., Skoff T. Pertussis.  [(accessed on 5 February 2024)]; Available online:  https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html.</Citation></Reference><Reference><Citation>r01e00000ff26d465eba470b8768b3b21eb0fa254, r01e00000ff26d46733a470b8eb7916b4c0d25229 Manual de Vacunaciones.  [(accessed on 27 February 2024)].  Available online:  https://www.euskadi.eus/informacion/manual-de-vacunaciones/web01-a2gaixo/es/</Citation></Reference><Reference><Citation>Spanish Ministry of Health.  [(accessed on 27 June 2024)].  Available online:  https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/S/sivamin.</Citation></Reference><Reference><Citation>González-López J.J., Álvarez Aldeán J., Álvarez García F.J., Campins M., Garcés-Sánchez M., Gil-Prieto R., Grande-Tejada A.M. Epidemiology, prevention and control of pertussis in Spain: New vaccination strategies for lifelong protection. Enfermedades Infecc. Microbiol. Clin. Engl. 2022;40:195–203. doi: 10.1016/j.eimc.2021.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eimc.2021.04.009</ArticleId><ArticleId IdType="pubmed">35473991</ArticleId></ArticleIdList></Reference><Reference><Citation>Red Nacional de Vigilancia Epidemiológica. Protocolos de la Red Nacional de Vigilancia Epidemiológica.  [(accessed on 15 March 2024)].  Available online:  https://cne.isciii.es/documents/d/cne/protocolo-de-vigilancia-de-tosferina.</Citation></Reference><Reference><Citation>Wang Z., Cui Z., Li Y., Hou T., Liu X., Xi Y., Liu Y., Li H., He Q. High prevalence of erythromycin-resistant Bordetella pertussis in Xi’an, China. Clin. Microbiol. Infect. 2014;20:O825–O830. doi: 10.1111/1469-0691.12671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12671</ArticleId><ArticleId IdType="pubmed">24816168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir-Cros A., Moreno-Mingorance A., Martín-Gómez M.T., Abad R., Bloise I., Campins M., González-Praetorius A., Gutiérrez M.N., Martín-González H., Muñoz-Almagro C., et al. Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986–2018. Emerg. Infect. Dis. 2022;28:967–976. doi: 10.3201/eid2805.211958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2805.211958</ArticleId><ArticleId IdType="pmc">PMC9045434</ArticleId><ArticleId IdType="pubmed">35447067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooi F.R., van Loo I.H., King A.J. Adaptation of Bordetella pertussis to vaccination: A cause for its reemergence? Emerg. Infect. Dis. 2001;7((Suppl. 3)):526–528. doi: 10.3201/eid0707.017708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0707.017708</ArticleId><ArticleId IdType="pmc">PMC2631860</ArticleId><ArticleId IdType="pubmed">11485646</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Hu D., Luu L.D.W., Octavia S., Keil A.D., Sintchenko V., Tanaka M.M., Mooi F.R., Robson J., Lan R. Genomic dissection of the microevolution of Australian epidemic Bordetella pertussis. Emerg. Microbes Infect. 2022;11:1460–1473. doi: 10.1080/22221751.2022.2077129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2077129</ArticleId><ArticleId IdType="pmc">PMC9176669</ArticleId><ArticleId IdType="pubmed">35543519</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark T.A., Messonnier N.E., Hadler S.C. Pertussis control: Time for something new? Trends Microbiol. 2012;20:211–213. doi: 10.1016/j.tim.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2012.03.003</ArticleId><ArticleId IdType="pubmed">22494804</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control . Increase of pertussis cases in the EU/EEA, 8 May 2024. ECDC; Stockholm, Sweden: 2024.</Citation></Reference><Reference><Citation>CNE—Tosferina.  [(accessed on 19 September 2024)].  Available online:  https://cne.isciii.es/servicios/enfermedades-transmisibles/enfermedades-a-z/tosferina.</Citation></Reference><Reference><Citation>Nordholm A.C., Emborg H.-D., Nørgaard S.K., Nygaard U., Ronayne A., Nielsen L.B., Søborg B., Andersen P.H., Dalby T. Pertussis epidemic in Denmark, August 2023 to February 2024. Euro Surveill. 2024;29:2400160. doi: 10.2807/1560-7917.ES.2024.29.14.2400160.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.14.2400160</ArticleId><ArticleId IdType="pmc">PMC11004589</ArticleId><ArticleId IdType="pubmed">38577803</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigl J.A., Bock H.L., Clemens R., Zepp F., Habermehl P., Beutel K., Müschenborn S., Sümenicht G., Schuind A., von König C.H., et al. Safety and efficacy of acellular pertussis vaccines: The Mainz study and other recent studies. Ann. Acad. Med. 1997;26:320–325.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285026</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmaso S., Mastrantonio P., Tozzi A.E., Stefanelli P., Anemona A., degli Atti M.L.C., Giammanco A. The Stage III Working Group Sustained Efficacy During the First 6 Years of Life of 3-Component Acellular Pertussis Vaccines Administered in Infancy: The Italian Experience. Pediatrics. 2001;108:e81. doi: 10.1542/peds.108.5.e81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.108.5.e81</ArticleId><ArticleId IdType="pubmed">11694665</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R., Ashman M., Taha M.-K., Varon E., Angoulvant F., Levy C., Rybak A., Ouldali N., Guiso N., Grimprel E. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect. Dis. Now. 2021;51:418–423. doi: 10.1016/j.idnow.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8114587</ArticleId><ArticleId IdType="pubmed">33991720</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcher T., Preston A. Bordetella pertussis evolution in the (functional) genomics era. Pathog. Dis. 2015;73:ftv064. doi: 10.1093/femspd/ftv064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femspd/ftv064</ArticleId><ArticleId IdType="pmc">PMC4626590</ArticleId><ArticleId IdType="pubmed">26297914</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkoff A.-M., Mertsola J., Pierard D., Dalby T., Hoegh S.V., Guillot S., Stefanelli P., van Gent M., Berbers G., Vestrheim D., et al. Pertactin-deficient Bordetella pertussis isolates: Evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill. 2019;24:1700832. doi: 10.2807/1560-7917.ES.2019.24.7.1700832.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.7.1700832</ArticleId><ArticleId IdType="pmc">PMC6381657</ArticleId><ArticleId IdType="pubmed">30782265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: Temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 1998;66:670–675. doi: 10.1128/IAI.66.2.670-675.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.66.2.670-675.1998</ArticleId><ArticleId IdType="pmc">PMC107955</ArticleId><ArticleId IdType="pubmed">9453625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooi F.R., He Q., van Oirschot H., Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 1999;67:3133–3134. doi: 10.1128/IAI.67.6.3133-3134.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.67.6.3133-3134.1999</ArticleId><ArticleId IdType="pmc">PMC96632</ArticleId><ArticleId IdType="pubmed">10338531</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandal L.T., Vestrheim D.F., Bruvik T., Roness R.B., Bjørnstad M.L., Greve-Isdahl M., Steens A., Brynildsrud O.B. Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019. Eur. J. Clin. Microbiol. Infect. Dis. 2022;41:913–924. doi: 10.1007/s10096-022-04453-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-022-04453-0</ArticleId><ArticleId IdType="pmc">PMC9135841</ArticleId><ArticleId IdType="pubmed">35543837</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosa F., du Plessis M., Weigand M.R., Peng Y., Mogale D., de Gouveia L., Nunes M.C., Madhi S.A., Zar H.J., Reubenson G., et al. Genomic characterization of Bordetella pertussis in South Africa, 2015–2019. Microb. Genom. 2023;9:001162. doi: 10.1099/mgen.0.001162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.001162</ArticleId><ArticleId IdType="pmc">PMC10763497</ArticleId><ArticleId IdType="pubmed">38117675</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarchi A., Octavia S., Nikbin V.S., Lotfi M.N., Zahraei S.M., Tay C.Y., Lamichhane B., Shahcheraghi F., Lan R. Genomic epidemiology of Iranian Bordetella pertussis: 50 years after the implementation of whole cell vaccine. Emerg. Microbes Infect. 2019;8:1416–1427. doi: 10.1080/22221751.2019.1665479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2019.1665479</ArticleId><ArticleId IdType="pmc">PMC6764348</ArticleId><ArticleId IdType="pubmed">31543006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.-S., Wang H.-M., Yao K.-H., Liu Y., Lei Y.-L., Deng J.-K., Yang Y.-H. Clinical characteristics, molecular epidemiology and antimicrobial susceptibility of pertussis among children in southern China. World J. Pediatr. 2020;16:185–192. doi: 10.1007/s12519-019-00308-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00308-5</ArticleId><ArticleId IdType="pubmed">31493136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooi F.R., van Loo I.H.M., van Gent M., He Q., Bart M.J., Heuvelman K.J., de Greeff S.C., Diavatopoulos D., Teunis P., Nagelkerke N., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 2009;15:1206–1213. doi: 10.3201/eid1508.081511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1508.081511</ArticleId><ArticleId IdType="pmc">PMC2815961</ArticleId><ArticleId IdType="pubmed">19751581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arciuolo R.J., Rosen J.B., Zucker J.R. Elevated Pertussis Reporting in Response to 2011–2012 Outbreak, New York City, New York, USA. Emerg. Infect. Dis. 2016;22:1117–1119. doi: 10.3201/eid2206.151514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2206.151514</ArticleId><ArticleId IdType="pmc">PMC4880097</ArticleId><ArticleId IdType="pubmed">27191867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow E.J., Uyeki T.M., Chu H.Y. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat. Rev. Microbiol. 2023;21:195–210. doi: 10.1038/s41579-022-00807-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00807-9</ArticleId><ArticleId IdType="pmc">PMC9574826</ArticleId><ArticleId IdType="pubmed">36253478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>